Myomo (MYO) Insider Heather Getz Buys 78,704 Shares
Heather Getz acquired 78,704 shares of Myomo, Inc., signaling insider confidence.
Reviewed by automated data checks against the source filing. How we make and check alerts
Heather Getz bought 78,704 shares of Myomo, Inc. ($MYO) on June 25, 2026. The trade was reported to the SEC in a Form 4 filing.
Since the trade, $MYO is down 4.6% after 1 week, down 1.9% after 1 month and up 11.1% to date (from the $1.08 close on Jun 25, 2026).
MYO
Myomo, Inc.
Key Points
- Heather Getz bought 78,704 shares of Myomo, Inc. on June 25, 2026, reflecting insider confidence.
- Myomo, Inc. trades near $1.14 with a market cap of approximately $39.8 million and a beta of 1.46.
- Analysts maintain a 'buy' rating with price targets ranging from $5.00 to $10.00.
Get $MYO trade alerts by text
We text you when insiders, Congress or big funds trade $MYO. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Myomo, Inc. alert may contain errors. Disclosures
Heather Getz, an insider at Myomo, Inc., purchased 78,704 shares of the company on June 25, 2026. This move adds to the insider confidence in the company as it continues to develop its medical robotics technology.
Insider Buying and Selling at Myomo, Inc.
Several insiders, including Heather Getz, Kirk Thomas, and Milton Mayo, each purchased 78,704 shares of Myomo, Inc. on June 25, 2026. These transactions were not part of a pre-planned trading program, suggesting a direct vote of confidence in the company's prospects.
Myomo, Inc. Stock Down 28.2%
Shares of NYSE American:MYO traded near $1.14 on Saturday. Myomo, Inc. has a market capitalization of about $39.8 million and a beta of 1.46, indicating its stock is somewhat more volatile than the market. The stock has seen a 52-week range between $0.60 and $2.38, with moving averages of $1.02 over 50 days and $0.92 over 200 days. The company maintains a current ratio of 2.734, suggesting good short-term financial health, but its debt-to-equity ratio of 210.649 indicates significant leverage.
Analysts Set New Price Targets
On June 8, 2026, Ascendiant Capital maintained its 'buy' rating for Myomo, Inc., with a price target of $10.00. The consensus among analysts is a 'buy' recommendation, with a mean target price of $4.42 based on five analyst opinions.
About Myomo, Inc.
Myomo, Inc. is a healthcare company based in Burlington, Massachusetts. It specializes in designing and producing myoelectric orthotics, which are wearable devices that assist individuals with neuromuscular disorders. The company's flagship product, MyoPro, helps support weak or paralyzed arms, improving daily activities for patients with conditions like stroke or spinal cord injuries. Led by CEO Paul R. Gudonis, Myomo employs 194 people and operates internationally, including in the United States and Germany.
Bottom Line
Heather Getz's recent purchase of shares in Myomo, Inc. underscores insider confidence in the company's future. Myomo is a key player in the medical devices sector, focusing on innovative solutions for neuromuscular disorders. While the stock remains volatile, analysts continue to see potential, maintaining favorable ratings and price targets. As always, remember that insider purchases are disclosed after the fact and should be considered as part of a broader investment analysis.
Related Filing Alerts
Source: Heather Getz's Form 4 filing on $MYO (Jun 25, 2026). Find the original filing: MYO Form 4 filings on SEC EDGAR. Written by software, not financial advice. How we make alerts